Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse

Not Applicable

Completed

• Conditions: Schizophrenia; Cannabis Dependence, Continuous
• Interventions: Behavioral: Usual care; Behavioral: Motivational therapy

• Registration Number: NCT00798109
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

Schizophrenia is a severe mental illness with a lifetime morbidity risk close to 1 %, involving both genetic and environmental risk factors. Prospective studies have shown that heavy use of cannabis in adolescence moderately increases the risk of developing schizophrenia. Many data have also suggested that the co-occurrence of cannabis abuse in patients with schizophrenia has a deleterious impact on the clinical outcome of schizophrenia. Cannabis abuse by schizophrenic patients is a significant public health problem for which there is no empirically validated treatment. We are presently studying the efficiency of motivational therapy on cannabis consumption in patients with schizophrenia.

Detailed Description

Schizophrenia is a severe mental illness with a lifetime morbidity risk close to 1 %, involving both genetic and environmental risk factors. Prospective studies have shown that heavy use of cannabis in adolescence moderately increases the risk of developing schizophrenia. Many data have also suggested that the co-occurrence of cannabis abuse in patients with schizophrenia has a deleterious impact on the clinical outcome of schizophrenia. Cannabis abuse by schizophrenic patients is a significant public health problem for which there is no empirically validated treatment. We are presently studying the efficiency of motivational therapy on cannabis consumption in patients with schizophrenia.

330 patients with schizophrenia and cannabis abuse or dependence (according to DSM-IV criteria) are randomly assigned to 4 motivational interview during one month or usual intensive treatment. Treatment is conducted in outpatient which are evaluated at the inclusion and at 6 month with Time-Line Follow Bach for the consumption, PANSS score, number of relapse...). A outcome measure was urinalysis results providing an objective measure of cannabis use throughout the six month of the trial.

Study Timeline

• Study First Submitted: 2008-09-30
• Study Start: 2008-11
• Study First Submitted QC: 2008-11-24
• Study First Posted: 2008-11-25
• Primary Completion: 2012-10
• Study Completion: 2013-04
• Status Verified: 2014-06
• Last Update Submitted: 2014-06-13
• Last Update Posted: 2014-06-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 97

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Usual Care	Usual care	Usual care with intensive psychotherapy
Motivational Therapy	Motivational therapy	Four motivational interview for cannabis abuse in schizophrenia population during one month

Primary Outcome Measures

Name	Time	Method
Cannabis consumption evaluated by the Time-Line Follow Back at 6 months with mean percentage of abstinent day	inclusion, 3 month, 6 month, 12 month

Secondary Outcome Measures

Name	Time	Method
PANSS, GAF, number of DSM-IV criteria of cannabis dependence, May scale for treatment response, SF-12, la URICA, number of hospitalisation, mean number of joints per week, D9THC urinanalysis at 6M and cannabis consumption evaluated by the TLFB at 6M	inclusion, 3 month, 6 month, 12 month. Only inclusion and 6 month for urianalysis	PANSS : global, positive, negative, general scores

Trial Locations

Locations (1)

Service de psychiatrie (Pr Adès); 🇫🇷 Colombes, France